Age Related Macular Degeneration

This is a Phase 1 clinical trial that aims to evaluate the safety, tolerability, and efficacy of a drug called axitinib in the OTX-TKI implant in participants with wet AMD.

Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years of age.

Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years of age. In the wet form of AMD, abnormal blood vessels grow in the back of the eye leaking blood or fluid that causes blurred or distorted vision.

The Queensland Eye Institute is currently involved in a phase 1 clinical trial that aims to evaluate the safety, tolerability, and efficacy of a drug called axitinib in the OTX-TKI implant in participants with wet AMD. The principal investigator involved in this study is A/Prof Anthony Kwan and the associate investigator involved is Dr Abhishek Sharma.

Criteria

Inclusion Criteria

  • Participants aged 50 years and over with wet AMD
  • Are able and willing to comply with all study requirements and visits

Exclusion Criteria

  • Participated in any study involving an investigational drug within the past 30 days
  • Women who are pregnant, nursing or of childbearing potential without adequate contraception

Age

50 years

Gender

Both

Title of the video goes here

Lorem ipsum set emit dolor

Please support our sight saving work

Your support will help us recruit the best researchers to develop better treatments, purchase the latest equipment, advance clinical trials of new treatments, improve eye health education, and support talented students to become tomorrow’s leaders in eye research.

Make a donation